Vermillion receives USPTO patent for PAD biomarker

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 7,867,719 entitled "Beta-2 microglobulin as a biomarker for Vermillion receives USPTO patent for Beta-2 microglobulin in detecting peripheral artery disease" to the Company. The patent claims are directed to Beta-2 microglobulin and biomarker combinations that include Beta-2 microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay. The studies underlying the patent were conducted with Dr. John P. Cooke, M.D., Ph.D., a Professor and Associate Director of the Stanford Cardiovascular Institute at Stanford University School of Medicine. Dr. Cooke is a founder and past President of the Society for Vascular Medicine, and an author of over 350 scientific articles in vascular medicine and biology.

"The issuance of this PAD biomarker patent will help our efforts to develop and commercialize our VASCLIRâ„¢ test for PAD. We continue to progress our PAD program, including the initiation of our intended use study," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.

Source:

Vermillion, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study demonstrates that TMPRSS2, which is key to SARS-CoV-2 cell entry, is a tumor suppressor